For decades, the randomized controlled clinical trial was the only currency the FDA accepted as proof of a drug’s safety and efficacy. That is changing. Real-world evidence — data generated outside the traditional clinical trial setting, from sources like electronic health records, insurance claims, and patient registries — is increasingly being used to support FDA decisions, from label expansions to, in select cases, original approvals. For biotech investors, understanding what real-world evidence is, where the FDA currently accepts it, and where its limitations remain is important for evaluating both regulatory strategy and post-approval commercial evidence generation.
The Short Answer
| Real-world evidence (RWE) is clinical evidence about the usage, benefits, and risks of a medical product derived from analysis of real-world data (RWD) — data collected outside the context of a traditional randomized controlled clinical trial. Sources of real-world data include electronic health records, medical claims and billing data, product and disease registries, and data gathered through personal devices and wearables. The FDA can use real-world evidence to support regulatory decisions including label expansions, post-approval study requirements, and in specific circumstances, original approval decisions. |
The Legislative Push Behind Real-World Evidence
The formal push to expand the FDA’s use of real-world evidence began with the 21st Century Cures Act, signed into law in December 2016. The Act directed the FDA to establish a program evaluating the potential use of real-world evidence to support approval of new indications for already-approved drugs and to help satisfy post-approval study requirements.
The rationale behind the push was practical: randomized controlled trials, while the scientific gold standard for establishing efficacy, are expensive, time-consuming, and often study a narrower patient population than the one that ultimately uses the drug in clinical practice. Real-world data — generated continuously through the healthcare system as patients are treated — offered the potential to answer questions that traditional trials could not efficiently address: how does a drug perform in older patients, in patients with multiple comorbidities, or over many years of use in routine clinical practice?
The FDA published its Real-World Evidence Framework in December 2018, outlining how the agency would evaluate the use of RWE in regulatory decision-making, and has since issued a series of more specific guidance documents addressing electronic health records, registries, and other data source considerations.
Where the FDA Currently Accepts Real-World Evidence
The most established use of real-world evidence is in post-market safety surveillance — monitoring approved drugs for rare or long-term adverse events that would not be captured in the more limited size and duration of pre-approval clinical trials. The FDA’s Sentinel Initiative, a national electronic system that actively monitors the safety of FDA-regulated products using real-world healthcare data, is one of the most established RWE infrastructure investments in the agency’s history.
Label expansions are the second major application. When a company seeks to expand an approved drug’s label — for example, adding a new patient subpopulation or a new dosing regimen — real-world evidence can sometimes support that expansion without requiring an entirely new randomized trial. Pfizer’s Ibrance received a label expansion for male breast cancer based substantially on real-world data, given the rarity of the condition made a dedicated randomized trial impractical.
Original drug approvals based primarily on real-world evidence remain rare and are typically limited to circumstances where randomized trials are genuinely impractical — extremely rare diseases with very small patient populations, or situations where withholding an established comparator arm would be unethical. The FDA continues to require randomized controlled trial data as the primary basis for most original approvals.
External Control Arms — A Growing RWE Application
One of the fastest-growing applications of real-world evidence is the external control arm — using real-world data about how a disease progresses in patients receiving standard treatment as a comparator, rather than enrolling a traditional randomized control group receiving placebo or standard of care within the trial itself. This is particularly relevant in rare diseases and oncology, where enrolling patients into a control arm that does not receive the experimental therapy may be difficult, unethical, or simply impractical given small patient populations.
External control arm approvals require rigorous statistical methodology to address the inherent biases of non-randomized comparisons — patients selected for a real-world cohort may differ systematically from clinical trial participants in ways that confound the comparison. The FDA has approved several rare disease and oncology drugs using external control arm data, but the bar for statistical rigor remains high.
What Real-World Evidence Means for Investors
For biotech investors, real-world evidence strategy is increasingly relevant to evaluating both regulatory risk and commercial evidence generation post-approval. Companies developing drugs for very rare diseases where randomized trials are difficult to execute may pursue an RWE-supported approval pathway — understanding this strategy, and the FDA’s historical acceptance rate for similar approaches, is useful context. Post-approval, real-world evidence is increasingly used to support payer negotiations and demonstrate comparative effectiveness against competing drugs, which can affect commercial uptake and pricing power.
What This Does Not Guarantee
| The availability of real-world data does not guarantee the FDA will accept it as sufficient evidence for approval or label expansion. The agency applies rigorous standards to real-world evidence, and many RWE-based submissions are found insufficient due to data quality issues, confounding, or inadequate statistical methodology. Companies pursuing an RWE-heavy regulatory strategy for a rare disease or difficult-to-study population still face meaningful regulatory risk, and investors should not assume an RWE pathway is a lower bar than a traditional randomized trial simply because it may be faster or less expensive to generate. |
Key Takeaways
- Real-world evidence (RWE) is clinical evidence derived from real-world data — electronic health records, claims data, registries — collected outside traditional randomized clinical trials
- The 21st Century Cures Act (2016) directed the FDA to formally evaluate expanded use of RWE in regulatory decision-making
- RWE is most established in post-market safety surveillance, including the FDA’s Sentinel Initiative
- Label expansions are a growing application, particularly for rare subpopulations where dedicated randomized trials are impractical
- External control arms — using real-world data as a comparator instead of a traditional randomized control group — are an increasingly used approach in rare disease and oncology drug development
- Original approvals based primarily on RWE remain rare and are reserved for circumstances where randomized trials are genuinely impractical or unethical
- RWE-based regulatory strategies are not a lower evidentiary bar — the FDA applies rigorous statistical scrutiny to address the inherent biases of non-randomized data
Sources
1. FDA — Real-World Evidence: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
2. 21st Century Cures Act: https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act
3. FDA — Sentinel Initiative: https://www.fda.gov/safety/fdas-sentinel-initiative
4. FDA — Real-World Evidence Framework: https://www.fda.gov/media/120060/download
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
